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httpStatin therapy is associated with improved survival
after endovascular and open aneurysm repair
Jorg L. de Bruin, MD,a Annette F. Baas, MD, PhD,b Martijn W. Heymans, PhD,c Mathijs G. Buimer, MD,a
Monique Prinssen, MD, PhD,b Diederick E. Grobbee, MD, PhD,b and Jan D. Blankensteijn, MD, PhD,a for
the DREAM Study Group, Amsterdam and Utrecht, The Netherlands
Background: The relationship between numerous risk factors and perioperative mortality after cardiovascular surgery has
been studied extensively. While improved perioperative survival and fewer cardiovascular events have been related to
statin therapy, its effect on long-term survival after aneurysm repair remains to be elucidated. The aim of this study is to
determine the effect of statin therapy on long-term survival after open and endovascular aneurysm repair and to identify
other cardiovascular and patient-related risk factors in this respect.
Methods: A post-hoc analysis of a randomized trial comparing open and endovascular abdominal aortic aneurysm repair
was performed. In this multicenter trial, 351 patients were randomly assigned to undergo either open abdominal aortic
aneurysm repair or endovascular repair. Patients who were on lipid-lowering medication at their inclusion in the trial
(n [ 135) were compared with those who were not (n [ 216).
Results: During 6 years of follow-up, 118 (33.6%) patients died after randomization. Statin therapy, baseline charac-
teristics, Society for Vascular Surgery/International Society for Cardiovascular Surgery risk factors, aneurysm size,
reinterventions, antiplatelet or anticoagulant agents, and b-blockers were used to identify prognostic factors inﬂuencing
survival. After identiﬁcation of signiﬁcant factors in a Kaplan-Meier analysis, a multivariable Cox regression analysis was
applied. Statin therapy at inclusion in the trial was independently associated with better overall survival after open or
endovascular aneurysm repair (hazard ratio [HR], 0.5; 95% conﬁdence interval [CI], 0.3-0.8; P [ .004). Statins were
especially associated with fewer cardiovascular deaths (HR, 0.4; 95% CI, 0.2-0.9; P [ .025). Several risk factors were
associated with poor survival after open and endovascular aneurysm repair: age >70 (HR, 3.4; 95% CI, 2.2-5.0; P < .001),
a history of cardiac disease at baseline (HR, 1.9; 95% CI, 1.3-2.8; P[ .001), and moderate/severe tobacco use (HR, 1.7;
95% CI, 1.2-2.5; P[ .004). Gender, aneurysm size, the need for reintervention, pulmonary disease, renal disease, carotid
disease, hypertension, diabetes mellitus, antiplatelet or anticoagulant agents, and b-blockers were not signiﬁcantly
associated with impaired long-term survival (P > .05).
Conclusions: Despite the limitations of a post-hoc analysis of a prospectively maintained trial, we conclude that statin
therapy at the beginning of the trial is independently associated with improved long-term survival after open or endo-
vascular aneurysm repair, while age above 70 years, a history of cardiovascular disease, and tobacco use are associated with
decreased long-term survival. (J Vasc Surg 2014;59:39-44.)Randomized trials have shown that endovascular
repair offers a perioperative survival beneﬁt over open
repair for patients with large abdominal aortic aneurysms
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://dx.doi.org/10.1016/j.jvs.2013.07.026Cardiovascular deaths in the endovascular aneurysm
repair group appear to contribute to this “catch-up”
mortality during the ﬁrst 2 postoperative years.5 Conse-
quently, long-term survival is equal for both types of aneu-
rysm repair,6,7 with cardiovascular and cancer as the main
causes of death. A recent Danish study showed an increased
risk for cardiovascular events and death after AAA repair
compared with the general population,8 suggesting
a potential beneﬁt of both aspirin and statin. In a systematic
review, statin therapy was shown to improve all-cause
survival after AAA repair, but this was a review of retrospec-
tive studies only.9-12 Several studies have suggested a bene-
ﬁcial effect of perioperative statin therapy in reducing
cardiovascular complications and deaths directly after
vascular surgery.14-20 To investigate the potential beneﬁcial
effect of statin therapy on long-term survival after aneu-
rysm repair, a post-hoc analysis was performed on patients
from the Dutch Randomized Endovascular Aneurysm
Management (DREAM) trial.
METHODS
A post-hoc analysis of the DREAM trial was per-
formed. The design and methods of the trial have been39
Table I. Baseline characteristics
No statin (n ¼ 216) Statin (n ¼ 135) P value
Randomization Open 106 (49) 72 (53) .445
Endovascular 110 (51) 63 (47)
Gender Male 199 (92) 123 (91) .842
Female 17 (8) 12 (9)
Age, years 71.2 6 6.8 68.5 6 6.2 <.001
Aneurysm size, mm 60.2 6 8.5 60.6 6 9.1 .676
b-blocking agents Without 126 (58) 57 (42) .004
With 90 (42) 78 (58)
Antiplatelet or anticoagulant therapy Without 60 (28) 22 (16) .014
With 156 (72) 113 (84)
Society for Vascular Surgery/International
Society for Cardiovascular Surgery risk factors
Diabetes mellitus No 198 (92) 118 (87) .395
Mild 15 (7) 15 (11)
Moderate 3 (1) 2 (2)
Severe 0 0
Tobacco No 78 (36) 66 (49) .048
Mild 47 (22) 31 (23)
Moderate 74 (34) 32 (24)
Severe 17 (8) 6 (4)
Hypertension No 105 (49) 48 (36) .040
Mild 71 (33) 47 (35)
Moderate 34 (16) 36 (27)
Severe 6 (3) 4 (3)
Carotid disease No 188 (87) 111 (82) .552
Mild 6 (3) 6 (4)
Moderate 15 (7) 14 (10)
Severe 7 (3) 4 (3)
Cardiac disease No 142 (66) 54 (40) <.001
Mild 63 (29) 66 (49)
Moderate 11 (5) 15 (11)
Severe 0 0
Renal disease No 196 (91) 126 (93) .560
Mild 19 (9) 9 (7)
Moderate 1 (1) 0
Severe 0 0
Pulmonary disease No 155 (72) 115 (85) .034
Mild 45 (21) 15 (11)
Moderate 15 (7) 5 (4)
Severe 1 (1) 0
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).
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vascular surgery departments at 26 centers in The
Netherlands and four centers in Belgium, with an AAA
of at least 5 cm in diameter and considered suitable candi-
dates for both techniques were randomly assigned to open
or endovascular repair. The trial was conducted according
to the Declaration of Helsinki and approved by the ethics
committee of each participating hospital. All data were
collected by the trial coordination center (Julius Center
for Health Sciences and Primary Care, University Medical
Center, Utrecht, The Netherlands). Patients were followed
prospectively at 30 days and 6, 12, 18, and 24 months after
the procedure. After the initial 2 years of close follow-up,
patients received a questionnaire every 6 months request-
ing information about the status of their mental and phys-
ical health, as well as information about visits to a general
practitioner or other physicians and hospital admissions.
Five years postoperatively, patients were contacted by tele-
phone, and the information obtained was cross-referencedwith their medical records. Between November 2008 and
February 2009 all patient records were scrutinized for
survival and causes of death. The causes of death were
determined by reviewing death certiﬁcates, medical
records, and, if necessary, by contacting involved physicians
(general practitioners, surgeons, and other specialists) and
patients’ relatives. An outcome-adjudication committee,
consisting of ﬁve vascular surgeons, classiﬁed the causes
of death in a blinded fashion and independently from one
another. Disagreements were resolved in a plenary
consensus meeting.
The causes of death were grouped into the following
categories: cardiovascular (myocardial infarction, conges-
tive heart failure, cardiac arrest, stroke), cancer, pulmonary,
miscellaneous, and unknown.
Patients who were on lipid-lowering medication at their
inclusion in the trial (n ¼ 135) were compared with those
who were not (n ¼ 216; Table I). At the time of the oper-
ation, we did not have missing data regarding statin use,
Fig 1. Kaplan-Meier estimates of survival between patients with or
without statins. The standard error of both survival estimates does
not exceed 10%; the maximum standard errors are 5.5% and 4.5%,
respectively, at the end of both curves.
Table II. Factors inﬂuencing all-cause mortality
identiﬁed with a multivariable Cox regression analysis
HR
95% CI
lower bound
95% CI
upper bound
P
value
Age >70 years 3.34 2.24 5.04 <.001
Gender 0.73 0.36 1.47 .377
Aneurysm size >70 mm 1.54 .95 2.49 .081
Reintervention 0.82 0.52 1.29 .383
Cardiac disease 1.94 1.33 2.81 .001
Pulmonary disease 1.06 0.69 1.62 .792
Renal disease 1.52 0.84 2.76 .169
Carotid disease 1.35 0.82 2.20 .241
Hypertension 0.92 0.63 1.35 .679
Diabetes 1.26 0.69 2.31 .451
Tobacco 1.73 1.19 2.52 .004
Statin 0.53 0.34 0.82 .004
Antiplatelet/anticoagulant 1.33 0.82 2.16 .250
b-blocker 0.89 0.60 1.33 .577
CI, Conﬁdence interval; HR, hazard ratio.
All the factors are adjusted for randomization group and mutually adjusted.
The bold numbers are signiﬁcant in the multivariable analysis.
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compare these groups on survival, outcomes were estimated
using Kaplan-Meier functions and compared using the log-
rank test. This trial was not designed to detect a difference
between patients with or without statin therapy; therefore,
we performed a multivariable analysis, correcting for impor-
tant confounding variables. The following variables were
used in a multivariable analysis: age above 70, gender, aneu-
rysm size above 70 mm, the need for reintervention, Society
for Vascular Surgery/International Society for Cardiovas-
cular Surgery risk factors (cardiac disease, pulmonary
disease, renal disease, carotid artery disease, hypertension,
diabetes mellitus, tobacco use), statin therapy, use of anti-
platelet or anticoagulant agents, and use of b-blockers.
The variables were mutually adjusted using a stepwise Cox
regression analysis. Each individual variable was adjusted
for randomization group in a primary model, and subse-
quently, each of the remaining variables was added to and
removed from this model. The variable with the strongest
inﬂuence on the primary regression coefﬁcient was then
added to the primary model, and the cycle was repeated
until none of the remaining variables inﬂuenced the primary
regression coefﬁcient by more than 10%. In this way, a ﬁnal
multivariable model was created based on each individual
variable. The hazard ratios (HRs) of the initial variable in
all ﬁnal models were reported as mutually adjusted HRs.
In addition, the association with lipid-lowering medica-
tion and causes of death (grouped as cardiovascular, cancer,
pulmonary, miscellaneous, and unknown) was analyzed in
order to understand the effect on all-cause mortality.
For descriptive statistics, continuous data are presented
as mean 6 standard deviation when normally distributed
and median and interquartile range in case of a non-
normal distribution.
A P value of less than .05 was considered statistically
signiﬁcant. All analyses were performed using SPSS 19.0
software (SPSS Inc, Chicago, Ill).
RESULTS
Between November 2000 and December 2003, 178
patients were randomly assigned to open repair and 173to endovascular repair. Baseline characteristics are pre-
sented in Table I. The median follow-up was 6.4 years
(range, 5.1 to 8.2 years). Information on survival was avail-
able for all patients at 5 years postoperatively, for 79% at
6 years and for 53% at 7 years.
The following causes of death were identiﬁed: cardio-
vascular (n ¼ 36; 30.5%), cancer (n ¼ 36; 30.5%), pulmo-
nary (n ¼ 12; 10.2%), miscellaneous (n ¼ 20; 16.9%), and
unknown (n ¼ 14; 11.9%).6
In the univariable risk-factor analysis, the absence of
statin therapy was signiﬁcantly associated with poor survival
(Fig 1). In the multivariable analysis, this factor maintained
its association with higher mortality (Table II); statin
therapy was associated with better long-term survival after
open or endovascular aneurysm repair (HR, 0.5; 95%
conﬁdence interval [CI], 0.3-0.8; P ¼ .004). Several other
factors were associated with reduced survival (Table II):
age >70 (HR, 3.4; 95% CI, 2.2-5.0; P < .001), cardiac
disease (HR, 1.9; 95% CI, 1.3-2.8; P ¼ .001), and
moderate/severe tobacco use (HR, 1.7; 95% CI, 1.2-2.5;
P ¼ .004).
Statin therapy was also associated with a reduced risk of
cardiovascular deaths (P ¼ .025; Fig 2). The inﬂuence of
statin therapy on other causes of death (cancer, pulmonary,
miscellaneous, and unknown) was not statistically signiﬁ-
cant. Gender, aneurysm size, the need for reintervention,
pulmonary disease, renal disease, carotid artery disease,
hypertension, diabetes mellitus, antiplatelet or anticoagu-
lant agents, and b-blockers did not signiﬁcantly inﬂuence
overall survival.
DISCUSSION
This prospective study showed statin therapy to be
independently associated with better long-term survival
after open or endovascular aneurysm repair. The associa-
tion between high levels of low-density lipoprotein
Fig 2. Kaplan-Meier Estimates of cardiovascular survival between
patients with or without statin use. The standard error of both
survival estimates does not exceed 10%; the maximum standard
errors are 4.3% and 3.6%, respectively, at the end of both curves.
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and death has been studied extensively.28-30 LDL is a strong
predictor for both mortality in patients with cardiovascular
disease and coronary heart disease in patients without overt
symptoms.28-30 Besides this effect, pleiotropic effects of
statins, inﬂuencing endothelial function, inﬂammatory
response, thrombus formation, and plaque stability, could
affect perioperative and long-term outcomes after cardio-
vascular surgery as well.10-24 Whatever the mechanism is,
reducing LDL cholesterol and improving lipid proﬁle in
a cohort of AAA patients can be expected to attenuate
the long-term cardiovascular disease and death.
Previous studies have showed better perioperative
outcomes of AAA repair with statin therapy.14,15,17,18,20
A reduction of mortality and perioperative cardiac events
was achieved by decreasing death from cardiovascular
causes or myocardial infarction in patients receiving lipid-
lowering therapy.14,15,17,18,20 Only a few studies showed
a possible beneﬁcial effect of statins on long-term survival
after aneurysm repair, but these were all retrospective.10-12
Lipid-lowering therapy improved all-cause mortality in
these studies; however, one study could only prove peri-
operative beneﬁt and no long-term survival beneﬁt after
endovascular aneurysm repair in high cardiac risk
patients.13
The long-term survival after elective aneurysm repair
has been improved over time despite change in the case-
mix toward older patients with more comorbidities.25
Long-term survival after endovascular and open aneurysm
repair are similar6,7; thus, decreasing long-term mortality
is not related to the introduction of endovascular aneurysm
repair.25
Other factors inﬂuencing survival in our population are
older age, cardiac disease, and tobacco use. Creating a Cox
regression model allows correcting for these factors. Anti-
platelet or anticoagulant agents and b-blockers are factors
that have been associated with improved survival after
cardiovascular surgery17,26-28 and could inﬂuence long-
term survival after aneurysm repair as well. Statin therapy
remains an independent predictor after adjusting for thesefactors and increases long-term survival after AAA repair
(open or endovascular).
This trial started enrolling patients in 2000, at which
time statins were not considered mandatory in cardiovas-
cular risk management of AAA patients in The
Netherlands. Our prospective trial with intensive follow-
up offers the opportunity to analyze the determinants of
long-term survival, without missing data or patients.
However, this study was not designed to detect a differ-
ence in survival between patients with or without lipid-
lowering medication. While we adjusted for a number of
potential confounding variables in the analyses, residual
confounding cannot be excluded.
A potential confounder in this study could be the level
of primary care related to statin therapy. However, the anti-
platelet/anticoagulant therapy or b-blockers did not inﬂu-
ence overall survival after aneurysm repair. An additional
analysis, not included in this paper, showed no statistically
signiﬁcant association between other antihypertensive
medication and crude survival.
Another potential confounder is medication change
over time, particularly initiation of statins in patients who
were grouped in the no-statin group at inclusion or,
conversely, discontinuation of statins or incomplete medi-
cation compliance in patients in the statin group. Both
scenarios, however, would work in favor of our conclusion
that statins have a beneﬁcial effect on long-term survival
because hypothetically, the effect-size of statins in these
situations will be larger if the no-statin group only included
patients who did not use statins at any time or if the statin
group were composed of patients who were compliant the
entire trial period. While we did not have information
about the patients taking medication after surgery or
compliance during follow-up, one could question whether
the long-term survival beneﬁt was due to taking statin at
the time of the operation or during follow-up. In this trial,
LDL or high-density lipoprotein cholesterol levels were not
measured in order to determine the effectiveness of statin
therapy. Hypothetically, if an unidentiﬁed subgroup
patients exists in whom statin treatment is inadequate or
ineffective, the overall effect could have been even greater
by optimizing treatment in these patients. In addition, at
the beginning of the trial, in the late nineties, the recom-
mended dosage of lipid-lowering medication was not as
high as current standards dictate, again suggesting that
the survival beneﬁt could have been larger if all patients
would have received adequate dosages of statins. The
speciﬁc formulation or dosage is not known of these
patients; therefore, we cannot conclude which type of
lipid-lowering therapy or dosage would beneﬁcially inﬂu-
ence our outcomes or decrease long-term survival.
On the same note, patients who received statins for an
indication (eg, high lipid levels or cardiac disease) are ex-
pected to have a higher a priori risk of events. This con-
founding by indication would again attenuate the true
risk reduction. Even if the event rates would have been
the same in the statin and no-statin groups in this trial, it
could have reﬂected a risk reduction in the group that,
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entitled to have an (untreated) elevated risk. Whether
crude survival and cardiovascular mortality is inﬂuenced
by non-fatal cardiovascular events is unknown in this trial.
This could clarify the beneﬁcial effect of statin therapy.
To identify the effect of statin therapy on long-term
survival, a randomized trial should be performed. Howe-
ver, one could question whether this study would be ethi-
cally justiﬁed and even feasible, given the available
evidence.
Convergence of all-cause mortality or “catch-up”
mortality between endovascular and open aneurysm repair
in the DREAM and EVAR-1 trials is largely explained by
higher rates of cardiovascular deaths in the endovascular
repair groups during the ﬁrst 2 years.5 Improving the
cardiovascular risk proﬁle with intensive vascular coun-
seling and optimal cardio-protective medication can play
key role in sustaining the beneﬁcial effect of endovascular
aneurysm repair postoperatively.
CONCLUSIONS
Despite the limitations of a post-hoc analysis of
a prospectively maintained trial, we conclude that statin
therapy at the beginning of the trial is independently asso-
ciated with improved long-term survival after open or
endovascular aneurysm repair, while age above 70 years,
cardiovascular disease, and moderate/severe tobacco use
are associated with decreased long-term survival. The ﬁnd-
ings support the view that statin treatment is an essential
element of risk management in patients undergoing aortic
aneurysm treatment.
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